Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid arthritis.
Autoimmune Disorders
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
AbbVie extends Rinvoq exclusivity by four years after generics settlements
Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases
IGI and AbbVie sign licence deal for cancer and autoimmune therapy
Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
Vor Bio back from brink with autoimmune drug deal rising to $4bn
US FDA approves GSK’s Benlysta autoinjector for lupus nephritis
